Multiple Myeloma |
The Royal Marsden Hospital, London, UK
Correspondence: Faith Davies, Haemato-oncology Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK. Phone: international +44.208.6613670. Fax: international +44.208.6429634. E-mail: faith.davies{at}icr.ac.uk
The combination of bortezomib (velcade), pulsed dexamethasone and weekly cyclophosphamide (CVD) in relapsed/refractory myeloma patients induces high overall (75%) and complete (31%) response rates compared to velcade/dexamethasone (overall 47%, CR 5%) and velcade alone (overall 27%, CR 0%). The toxicity profiles including thrombocytopenia, neutropenia, and neuropathy were comparable between the groups.
Key words: cyclophosphamide, velcade and dexamethasone (CVD), comparable toxicity, high response rates.
This article has been cited by other articles:
![]() |
H. Ludwig, M. Beksac, J. Blade, M. Boccadoro, J. Cavenagh, M. Cavo, M. Dimopoulos, J. Drach, H. Einsele, T. Facon, et al. Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective Oncologist, January 1, 2010; 15(1): 6 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Q. Lacy, S. R. Hayman, M. A. Gertz, A. Dispenzieri, F. Buadi, S. Kumar, P. R. Greipp, J. A. Lust, S. J. Russell, D. Dingli, et al. Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma J. Clin. Oncol., October 20, 2009; 27(30): 5008 - 5014. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Johnson, S. Corthals, C. Ramos, A. Hoering, K. Cocks, N. J. Dickens, J. Haessler, H. Goldschmidt, J. A. Child, S. E. Bell, et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping Blood, December 15, 2008; 112(13): 4924 - 4934. [Abstract] [Full Text] [PDF] |
||||